

### 43. Hubei Biocause Pharmaceutical Co., Ltd.

<b>Company name</b>	Hubei Biocause Pharmaceutical Co., Ltd. (a publicly traded company at Shenzhen Stock Exchange)
<b>Service scope</b>	Engaged in manufacturing and marketing of APIs and finished drugs; is the largest producer of Ibuprofen powder and tablets in China; also have outsourcing service for contract manufacturing.
<b>Technical capability</b>	Process R&D including synthetic route scouting and method development, pilot plant scale up; also capable of manufacturing cGMP materials to support clinical trials.
<b>Facility</b>	Own six manufacturing facilities and three research labs; also own 8 cGMP workshops.
<b>cGMP certification status</b>	Passed SFDA's cGMP inspection; API of Ibuprofen received Certificate of Suitability (COS) from EDQM and US FDA's DMF serial number.
<b>Capacity/scale</b>	Ibuprofen powder and tablets: 3,000 metric tons and 4 billion tablets.
<b>Products to offer</b>	Ibuprofen, (S)-(+)-Ibuprofen, Ibuprofen Lysine, Oxaprozin, Balsalazide Sodium, Gatifloxacin, DL Naproxen, Fludarabine phosphate, Granisetron Hydrochloride, Milrinone, Flumazenil, Mitoxantrone Hydrochloride, Valganciclovir Hydrochloride, Clindamycin Palmitate Hydrochloride, Mecamylamine, Atreonom.
<b>Experience and Customers served</b>	Products sold to 46 countries.
<b>Year established</b>	1993
<b>Number of scientific employees</b>	N/A (total staff companywide: 1,800)
<b>Contact</b>	No. 132 Yangwan Road, Jingmen, Hubei 448000 China Tel: 86-724-2211112 Fax: 86-724-2211900 E-mail: <a href="mailto:tomwang@biocause.net">tomwang@biocause.net</a> <a href="http://www.biocause.com">http://www.biocause.com</a>